FDA approves higher-dose Wegovy injection at 7.2 mg for weight loss

On March 19, 2026, the FDA approved a higher dose of Wegovy, called Wegovy HD, for weight loss in adults with obesity. The new version is a once-weekly semaglutide injection of 7.2 mg, triple the previous highest dose of 2.4 mg ^[1][2]. Novo Nordisk, which makes Wegovy, says the product will be available in the U.S. in April 2026 ^[1][2].

The label says Wegovy HD is for adults who have tolerated the 2.4 mg dose for at least four weeks and for whom additional weight loss is clinically indicated, used along with a reduced-calorie diet and increased physical activity ^[1]. The company has not announced what it will cost ^[2].

What the trial found

The approval is based on STEP UP, a 72-week phase 3b trial that enrolled 1,407 adults with obesity (BMI 30 or higher) who did not have diabetes. Participants were randomly assigned in a 5:1:1 ratio to weekly semaglutide 7.2 mg, semaglutide 2.4 mg, or placebo, all with a lifestyle intervention ^[1].

Average weight loss at 72 weeks, counting only patients who stayed on treatment, was about 21% (20.7%) with 7.2 mg, about 18% (17.5%) with 2.4 mg and about 2% (2.4%) with placebo ^[1]. Counting all patients regardless of whether they stayed on treatment, the figures were about 19% (18.8%) with 7.2 mg, about 16% (15.5%) with 2.4 mg and about 4% (3.9%) with placebo ^[1]. A separate summary gives those all-patients numbers as 18.7%, 15.6% and 3.9%, with a p-value below 0.0001 — a rounding difference from the company's figures ^[2].

About 31% of participants on 7.2 mg (31.2%) lost 25% or more of their body weight, compared with 15.3% on 2.4 mg and 0% on placebo. And 89% of those on 7.2 mg lost at least 5% of body weight, versus 38% on placebo ^[1]. Mean starting weight was 248 pounds in the 7.2 mg and placebo groups and 257 pounds in the 2.4 mg group ^[1].

"The weight loss demonstrated with Wegovy HD could reshape healthcare professionals' expectations about what outcomes are possible for their patients with Wegovy," said W. Timothy Garvey, MD, professor of medicine and director of the Diabetes Research Center at the University of Alabama at Birmingham ^[1].

Side effects

Gastrointestinal side effects were more common at 7.2 mg than at 2.4 mg — 70.8% versus 61.2% ^[2]. The most common side effects reported with Wegovy HD were nausea, vomiting, dysesthesia, constipation, abdominal pain, fatigue, headache, dizziness, hair loss and flatulence ^[1].

Dysesthesia — an altered or unpleasant skin sensation such as burning or tingling — was reported by 22% of participants on 7.2 mg, compared with 6% on 2.4 mg and 0.3% on placebo ^[1]. Another summary puts those figures at 22.9% and 6.0% ^[2].

Why it matters for patients

The approval creates a second step for people who are already on semaglutide 2.4 mg and want more weight loss. It is not an option for someone starting treatment: the label requires at least four weeks on 2.4 mg first ^[1]. Even then, the added weight loss is a few percentage points on average, and it comes with more nausea, vomiting and other gastrointestinal effects, plus a higher rate of skin-sensation symptoms that were uncommon at the lower dose ^[1][2].

The existing Wegovy label includes an indication to reduce the risk of major cardiovascular events such as death, heart attack or stroke in adults with known heart disease and with obesity or overweight ^[1]. The announcement does not state whether the 7.2 mg dose carries that indication; that has not been disclosed ^[1].

What happens next

Wegovy HD is expected to reach the U.S. market in April 2026 through the same channels as Wegovy, including more than 70,000 pharmacies such as CVS and Costco, select telehealth providers, NovoCare Pharmacy and GoodRx ^[1]. Novo Nordisk says information on coverage and savings options for eligible patients will be available at that time ^[1]. Pricing has not yet been announced ^[2].